Use Case: A Patient-Centric Approach To Site Selection

Delve into the importance of a patient-centric approach in optimizing site and investigator selection for clinical trials in IgA Nephropathy (IgAN). Leveraging Citeline's comprehensive datasets and real-world evidence, this strategy focuses on understanding the patient journey, unmet needs, and the trial landscape to enhance recruitment and ensure successful trial outcomes. With IgAN's varied symptoms and late diagnosis challenges, with methods that prioritize patient demographics, location, and diversity to align study protocols with patient needs.

Citeline's tools, such as Trialtrove and Sitetrove, facilitate the identification of experienced investigators and suitable sites, emphasizing proximity to diverse patient populations. By incorporating heat maps and referral networks, the approach ensures the recruitment of trusted nephrologists and timely clinical trial site start-up. This patient-centric model not only addresses the low enrollment rates in Phase III trials but also ensures that patients receive appropriate and timely treatment. The integration of diversity action plans further bolsters the recruitment strategy, making it more inclusive and representative of the global IgAN population. This paper provides further details on how data-driven insights can transform clinical trial strategies, ultimately improving patient outcomes in rare diseases like IgAN.